TipRanks on MSN

HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal

Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...
Open Heart

Association of blood pressure control with atrial and ventricular ectopy in SPRINT

Background Previous epidemiological studies demonstrated that premature atrial contractions (PACs) and premature ventricular ...
Rutland Herald

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment

Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a ...

The heart condition that spikes during the festive season

"Holiday heart", or alcohol-induced atrial arrhythmia, is an irregular heartbeat commonly brought on by excessive or binge ...
BC Technology

SFU Announces New Gel-Free ECG Heart Monitoring System Combining 3D Printing and Artificial Intelligence for Faster Diagnoses

A new heart monitoring system combining 3D printing and artificial intelligence could transform the way doctors measure and ...
Medical Design & Outsourcing

The importance of ADCs in low-power electrocardiography ASICs

Standard ADC components seldom provide enough flexibility to meet the conflicting needs of today’s medical designs. By Ian ...

Investornewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal

Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal. HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through ...